The specialist cancer drug discovery and development business has reported HY December 2016 results registering a maiden net profit of £573k driven by the licensing deal agreed in September 2016 with Sierra Oncology (NASDAQ:SRRA). In H1, Sareum booked a £1.3m share of profits on the initial up-front payment. Post year end, a further £0.45m share from the first milestone payment, has left the Company confident of reporting a modest full year profit. We are forecasting a FY Ju
